The promotion of olanzapine in primary care: An examination of internal industry documents

Social Science and Medicine

Volumn 69, Issue 1, 2009, Pages 14-20

  Spielmans, Glen I ^a  

^a METROPOLITAN STATE UNIVERSITY   (United States)

Author keywords

Bipolar disorder; Dementia; Disease mongering; Marketing; Olanzapine; Pharmaceutical companies; Primary care; US Department of Justice

Indexed keywords

OLANZAPINE;

DISEASE TREATMENT; MARKETING; MENTAL HEALTH; PHARMACEUTICAL INDUSTRY; PRIMARY HEALTH CARE;

ARTICLE; BIPOLAR DISORDER; DEMENTIA; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; LAW SUIT; OFF LABEL DRUG USE; PRIMARY MEDICAL CARE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DEMENTIA; DOCUMENTATION; DRUG INDUSTRY; HUMANS; MARKETING; PRIMARY HEALTH CARE; SCHIZOPHRENIA;

NORTH AMERICA; UNITED STATES;

EID: 67649357231     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2009.05.001     Document Type: Article

References (86)

1. Angelmar R., Angelmar S., and Kane S. Building strong condition brands. Journal of Medical Marketing 7 (2007) 341-351
2. Anonymous. Zyprexa kills directory. Available from (2007). http://www.boocompany.com/zyprexakills/ Accessed 15.02.07
3. Antonuccio D.O., Danton W.G., and McClanahan T.M. Psychology in the prescription era: building a firewall between marketing and science. American Psychologist 58 (2003) 1028-1043
4. Applbaum K. The marketing era (2004), Routledge, NY
5. Bandick M. Zyprexa - primary care strategy and implementation overview. Available from (2000). http://www.furiousseasons.com/zyprexa%20documents/ZY100589868.pdf Accessed 15.02.07
6. Bandick M. Zyprexa primary care presentation. Available from (2000). http://www.furiousseasons.com/zyprexa%20documents/ZY100041630.pdf Accessed 15.02.07
7. Berenson A. Drug files show maker promoted unapproved use. New York Times (December 18, 2006) A1
8. Berenson A. Mother wonders if psychosis drug helped kill son. New York Times (January 4, 2007) A1
9. Berenson A. U.S. wonders if drug data was accurate. New York Times (January 5, 2007) C6
10. Berenson A. States study marketing of Lilly pill. New York Times (January 20, 2007) C1
11. Berenson A. 33 states to get $62 million in Zyprexa case settlement. New York Times (October 6, 2008) B7
12. Bogenschutz M.P., and Nurnberg H.G. Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry 65 (2004) 104-109
13. Crespo-Facorro B., Perez-Iglesias R., Ramirez-Bonilla M., Martinez-Garcia O., Llorca J., and Luis Vazquez-Barquero J. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. Journal of Clinical Psychiatry 67 (2006) 1511-1521
14. Dawdy P. (February 2007). http://www.furiousseasons.com/zyprexadocs.html Accessed February 15, 2007
15. De Deyn P.P., Carrasco M.M., Deberdt W., Jeandel C., Hay D.P., Feldman P.D., et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry 19 (2004) 115-126
16. Demer L. Anchorage attorney ordered to return documents on drug; Zyprexa: judge says publicized papers meant to be sealed were stolen. Anchorage Daily News (February 14, 2007) B2
17. Dobbs D. Email correspondence (subject: Zyprexa questions from the field). Available from (2000). http://www.furiousseasons.com/zyprexa%20documents/ZY100810986.pdf Accessed 15.02.07
18. Eaton M.L., and Xu M. Developing and marketing a blockbuster drug: Lessons from Eli Lilly's experience with Prozac (2005), Harvard Business School Press, Boston
19. Eli Lilly. Zyprex - a major step toward a health care solution for psychosis. Available from (1995). http://www.furiousseasons.com/zyprexa%20documents/ZY200269693.pdf Accessed 15.02.07
20. Eli Lilly. (1999). PCP-APS. Available from http://www.furiousseasons.com/zyprexa%20documents/ZY100041080.pdf. Accessed 15.02.07.
21. Eli Lilly. Zyprexa launch meeting. Available from (2000). http://www.furiousseasons.com/zyprexa%20documents/ZY100175096.pdf Accessed 15.02.07
22. Eli Lilly. Zyprexa product team off-site: July 25, 2001. Available from (2001). http://www.furiousseasons.com/zyprexa%20documents/ZY201548768.pdf Accessed 15.02.07
23. ® (olanzapine) primary care Q3 implementation guide. Available from (2001). http://www.furiousseasons.com/zyprexa%20documents/ZY100520636.pdf Accessed 15.02.2007
24. Eli Lilly. Hyperglycemia/diabetes: sell sheet implementation. Available from (2001). http://www.furiousseasons.com/zyprexa%20documents/ZY200098771.pdf Accessed 15.02.07
25. Eli Lilly. Zyprexa primary care CTNR. Available from (2001). http://www.furiousseasons.com/zyprexa%20documents/ZY100040886.pdf Accessed 15.02.07
26. Eli Lilly. 2001 Integrated product plan: Zyprexa product team. Available from (2001). http://www.furiousseasons.com/zyprexa%20documents/ZY201249534.pdf Accessed 15.02.07
27. Eli Lilly. Zyprexa US business plan - executive summary: Gerhard Mayr review - October 17, 2002. Available from (2002). http://www.furiousseasons.com/zyprexa%20documents/ZY201212010.pdf Accessed 15.02.07
28. Eli Lilly. Zyprexa primary care sales force resource guide. Available from (2002). http://www.furiousseasons.com/zyprexa%20documents/ZY200061996.pdf Accessed 15.02.07
29. Eli Lilly. Zyprexa PCP moderator slides. Available from (2002). http://www.furiousseasons.com/zyprexa%20documents/ZY200084169.pdf Accessed 15.02.07
30. ® (olanzapine). Available from (2002). http://www.furiousseasons.com/zyprexa%20documents/ZY200083405.pdf Accessed 15.02.07
31. Eli Lilly. Key player playbook. Available from (2002). http://www.furiousseasons.com/zyprexa%20documents/ZY100174816.pdf Accessed 15.02.07
32. Eli Lilly. Zyprexa product team SMEC pre-read. Available from (2002). http://www.furiousseasons.com/zyprexa%20documents/ZY201539804.pdf Accessed 15.02.07
33. Eli Lilly. Untitled. Available from (2003). http://www.furiousseasons.com/zyprexa%20documents/ZY1%20%20%2000014182.p df Accessed 15.02.07
34. Eli Lilly. Brand council I - 2003. Available from (2004). http://www.furiousseasons.com/zyprexa%20documents/ZY200370406.pdf Accessed 15.02.07
35. Eli Lilly. Lilly resolves investigations of past Zyprexa marketing and promotional practices. Available from (2009). http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=359242 Accessed l.04.09
36. Eli Lilly (undated-a). Zyprexa complicated mood project. Available from http://www.furiousseasons.com/zyprexa%20documents/ZY100582035.pdf. Accessed 15.02.07.
37. Eli Lilly. (undated-b). Zyprexa "frequent areas of concern" or "FAOC" Available from http://www.furiousseasons.com/zyprexa%20documents/ZY200083622. pdf. Accessed 15.02.07.
38. Eli Lilly. (undated-c). Patient/dosing clarity document. Available from http://www.furiousseasons.com/zyprexa%20documents/ZY200083385.pdf. Accessed 15.02.07.
39. Eli Lilly. (undated-d). PCP discussion guide. Available from http://www.furiousseasons.com/zyprexa%20documents/ZY200084171.pdf. Accessed 15.02.07.
40. Eli Lilly. (undated-e). Zyprexa retail implementation guide. Available from http://www.furiousseasons.com/zyprexa%20documents/ZY100040668.pdf. Accessed 15.02.07.
41. Gianfrancesco F., Wang R.H., and Nasrallah H.A. The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy. Annals of Clinical Psychiatry 18 (2006) 9-17
42. Glaser B.G., and Strauss A.L. The discovery of grounded theory (1967), Aldine, Chicago
43. Goldstein B. How Lilly sells Zyprexa. Slate (2007). http://www.slate.com/id/2159880/entry/2159881/ Available from
44. Grant B.F., Stinson F.S., Hasin D.S., Dawson D.A., Chou S.P., Ruan W.J., et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and related conditions. Journal of Clinical Psychiatry 66 (2005) 1205-1215
45. Guo J.J., Keck Jr. P.E., Corey-Lisle P.K., Li H., Jiang D., Jang R., et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. Journal of Clinical Psychiatry 67 (2006) 1055-1061
46. Guo J.J., Keck Jr. P.E., Corey-Lisle P.K., Li H., Jiang D., Jang R., et al. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. Pharmacotherapy 27 (2007) 27-35
47. Hall R.J., and Berlin R.J. When you have a hammer everything looks like a nail: misapplication of the False Claims Act to off-label promotion. Food and Drug Law Journal 61 (2006) 653-677
48. Healy D. Let them eat Prozac (2004), New York University Press, NY
49. Healy D. The latest mania: selling bipolar disorder. PLoS Medicine 3 (2006) e185
50. Hisey T. The big squeeze. Pharmaceutical Executive 24 (2004) 86-98. Available from http://pharmexec.findpharma.com/pharmexec/article/articleDetail.jsp?id=1 29292 Accessed 08.06.07
51. Hobson V.A. Email correspondence (subject: Dr. Leming letter). Available from (2001). http://www.furiousseasons.com/zyprexa%20documents/ZY100629545.pdf Accessed 15.02.07
52. IMS Health. (2000). Leading products by global sales. Accessed 04.05.07.
53. IMS Health. (2001). Leading products by global pharmaceutical sales. Accessed 04.05.07.
54. IMS Health. (2002). Leading products by global pharmaceutical sales. Accessed 04.05.07.
55. IMS Health. (2003). Leading products by global pharmaceutical sales. Accessed 04.05.07.
56. IMS Health. (2004). Leading products by global pharmaceutical sales. Accessed 04.05.07.
57. I.M.S.Health. (2005). Accessed 04.05.07.
58. IMS Health. (2006). Available: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFi le/Top_Line_Data/Leading%20Products%20by%20Global%20Pharmaceutical%20Sal es%202006.pdf. Accessed 04.05.07.
59. IMS Health. Top ten global products. Available from (2007). http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFi le/Top_Line_Data/Top10GlobalProducts.pdf Accessed 01.04.09
60. Judd L.L., and Akiskal H.S. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. Journal of Affective Disorders 73 (2003) 123-131
61. Kahan J.S., and Shapiro J.K. The first amendment and the food and drug administration's regulation of labeling and advertising: three proposed reforms. Food and Drug Law Journal 58 (2003) 353-364
62. Kinon B.J., Noordsy D.L., Liu-Seifert H., Gulliver A.H., Ascher-Svanum H., and Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. Journal of Clinical Psychopharmacology 26 (2006) 453-461
63. Lambert B.L., Cunningham F.E., Miller D.R., Dalack G.W., and Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. American Journal of Epidemiology 164 (2006) 672-681
64. Lopatto E. Eli Lillys fourth-quarter profit gains on cymbalta. Bloomberg News (2008). Available from www.bloomberg.com/apps/news?pid=conewsstory&refer=conews&tkr=LLY :US&sid=a23IUhqwpGaQ Accessed 07.02.08
65. Moynihan R., and Cassels A. Selling sickness (2005), Nation Books
66. Moynihan R., and Henry D. The fight against disease mongering: generating knowledge for action. PLoS Medicine 3 (2006) e191
67. Newcomer J.W., and Haupt D.W. The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry 51 (2006) 480-491
68. Ofek E. Eli Lilly: Developing cymbalta (2007), Harvard Business School Press, Boston
69. O'Reilly J., and Dalal A. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs. Annals of Health Law 12 (2003) 295-324
70. Porat Z. Research summary and recommendations first quarter 2002: zyprexa in primary care. Available from (2002). http://www.furiousseasons.com/zyprexa%20documents/ZY100027106.pdf Accessed 15.02.07
71. Robinson D.G., Woerner M.G., Napolitano B., Patel R.C., Sevy S.M., Gunduz-Bruce H., et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. American Journal of Psychiatry 163 (2006) 2096-2102
72. Schneider L.S., Dagerman K., and Insel P.S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry 14 (2006) 191-210
73. Schneider L.S., Tariot P.N., Dagerman K.S., Davis S.M., Hsiao J.K., Ismail M.S., et al., CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine 355 (2006) 1525-1538
74. Siegel M. Pressured to prescribe: the drug rep was only too happy to fill his sample closet with an antipsychotic. Los Angeles Times (December 25, 2006) F3
75. Silverman E. Overstated claims hurt: cymbalta ad is skewered. Available from (2008). http://www.pharmalot.com/2008/01/overstated-claims-hurt-cymbalta-ad-is-s kewered/ Accessed 03.01.08
76. Spielmans G.I. Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis. Psychotherapy and Psychosomatics 77 (2008) 12-16
77. Steinman M.A., Bero L.A., Chren M.M., and Landefeld C.S. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Annals of Internal Medicine 145 (2006) 284-293
78. Strassnig M., Miewald J., Keshavan M., and Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one- year analysis. Schizophrenia Research 93 (2007) 90-98
79. Takahashi H., Kamata M., Yoshida K., Ishigooka J., and Higuchi H. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. Journal of Clinical Psychiatry 67 (2006) 1577-1582
80. Thase M.E., Corya S.A., Osuntokun O., Case M., Henley D.B., Sanger T.M., et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment- resistant major depressive disorder. Journal of Clinical Psychiatry 68 (2007) 224-236
81. Tollefson G.D. Zyprexa product team 4-column summary. Available from (1997). http://www.furiousseasons.com/zyprexa%20documents/ZY200270343.pdf Accessed 15.02.07
82. United States Department of Justice. Eli Lilly and company agrees to pay $1.415 billion to resolve allegations of off-label promotion of Zyprexa. Available from (January 15, 2009). http://www.usdoj.gov/opa/pr/2009/January/09-civ-038.html Accessed 16.01.09
83. Weissman M.M., Bland R.C., Canino G.J., Faravelli C., Greenwald S., Hwu H.G., et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 276 (1996) 293-299
84. Woloshin S., and Schwartz L.M. Giving legs to restless legs syndrome. PLoS Medicine 3 (2006) e170
85. Woodcock J. A shift in the regulatory approach. Available from (1997). http://www.fda.gov/cder/present/diamontreal/regappr/sld006.htm Accessed 18.05.07
86. Zyprexa Litigation, et al. 07-CV-0504 (E.D. NY 2007). Available from (2007). http://www.eff.org/legal/cases/zyprexa/zyprexa_judgement.pdf Accessed 18.05.07